Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab with paclitaxel/carboplatin versus paclitaxel/carboplatin in previously untreated lung cancer
2007-001256-39Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ipilimumab in bronchial carcinoma, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Immune-related progression-free survival. Started Nov 2007; status: completed.
02
Drugs
ipilimumab
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2007-001256-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001256-39.